These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 8082521)

  • 1. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
    Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S
    Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Split-mixed insulin regimen with human ultralente before supper and NPH (isophane) before breakfast in children and adolescents with IDDM.
    Wolfsdorf JI; Laffel LM; Pasquarello C; Vernon A; Herskowitz RD
    Diabetes Care; 1991 Nov; 14(11):1100-6. PubMed ID: 1797498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study.
    Taylor R; Davies R; Fox C; Sampson M; Weaver JU; Wood L
    Diabetes Care; 2000 Nov; 23(11):1612-8. PubMed ID: 11092282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of human ultralente- and lente-based twice-daily injection regimens.
    Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
    Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of early-morning hyperglycemia in IDDM patients with long-acting zinc insulin.
    Parillo M; Mura A; Iovine C; Rivellese AA; Lavicoli M; Riccardi G
    Diabetes Care; 1992 Feb; 15(2):173-7. PubMed ID: 1547673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen.
    Rabasa-Lhoret R; Garon J; Langelier H; Poisson D; Chiasson JL
    Diabetes Care; 1999 May; 22(5):667-73. PubMed ID: 10332663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term use of intramuscular insulin therapy in a type I diabetic patient with subcutaneous insulin resistance.
    Brossard JH; Havrankova J; Rioux D; Bertrand S; D'Amour P
    Diabet Med; 1993 Mar; 10(2):174-6. PubMed ID: 8458196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal activity profiles of NPH and [Nepsilon-palmitoyl Lys (B29)] human insulins in subjects with IDDM.
    Radziuk J; Pye S; Bradley B; Braaten J; Vignati L; Roach P; Bowsher R; DiMarchi R; Chance R
    Diabetologia; 1998 Jan; 41(1):116-20. PubMed ID: 9498640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB; Mallias J; Home PD
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of beef ultralente for basal insulin delivery: plasma insulin concentrations after chronic ultralente administration in patients with IDDM.
    Rizza RA; O'Brien PC; Service FJ
    Diabetes Care; 1986; 9(2):120-3. PubMed ID: 3698778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
    Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
    Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice-daily humulin ultralente insulin decreases morning fasting hyperglycemia.
    Johnson NB; Kronz KK; Fineberg NS; Golden MP
    Diabetes Care; 1992 Aug; 15(8):1031-3. PubMed ID: 1505304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nocturnal blood glucose control in type I diabetes mellitus.
    Bolli GB; Perriello G; Fanelli CG; De Feo P
    Diabetes Care; 1993 Dec; 16 Suppl 3():71-89. PubMed ID: 8299480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes.
    Kudva YC; Basu A; Jenkins GD; Pons GM; Quandt LL; Gebel JA; Vogelsang DA; Smith SA; Rizza RA; Isley WL
    Diabetes Care; 2005 Jan; 28(1):10-4. PubMed ID: 15616226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia.
    Francis AJ; Hanning I; Alberti KG
    Diabetes Res; 1986 Jun; 3(5):263-8. PubMed ID: 3527523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles.
    Lindström T; Olsson PO; Arnqvist HJ
    Scand J Clin Lab Invest; 2000 Aug; 60(5):341-7. PubMed ID: 11003253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the safety and effectiveness of human and bovine long-acting insulins.
    Selam JL; Turner D; Woertz L; Eichner HL; Lauritano A; Charles MA
    Diabetes Res; 1989 Nov; 12(3):131-4. PubMed ID: 2635094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.